CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model ; volume:11 ; number:1 ; day:10 ; month:5 ; year:2022 ; pages:1-13 ; date:12.2022
Experimental hematology & oncology ; 11, Heft 1 (10.5.2022), 1-13, 12.2022
- Creator
-
Chauchet, Xavier
Cons, Laura
Chatel, Laurence
Daubeuf, Bruno
Didelot, Gérard
Moine, Valéry
Chollet, Didier
Malinge, Pauline
Pontini, Guillemette
Masternak, Krzysztof
Ferlin, Walter
Buatois, Vanessa
Shang, Limin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-022-00279-w
- URN
-
urn:nbn:de:101:1-2022071619212133364326
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:19 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chauchet, Xavier
- Cons, Laura
- Chatel, Laurence
- Daubeuf, Bruno
- Didelot, Gérard
- Moine, Valéry
- Chollet, Didier
- Malinge, Pauline
- Pontini, Guillemette
- Masternak, Krzysztof
- Ferlin, Walter
- Buatois, Vanessa
- Shang, Limin
- SpringerLink (Online service)
Other Objects (12)
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Effector T cells against cancer
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Effector T cells against cancer
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Bi-specific Aptamers mediating Tumour Cell Lysis
CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
Effector T cells against cancer